Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q2 2022 Results Conference Call August 3, 2022 4:30 PM ET

Company Participants

Karina Calzadilla - Head, IR

Chad Robins - Co-Founder, CEO

Tycho Peterson - CFO

Nitin Sood - CCO, MRD

Sharon Benzeno - Head, Immune Medicine

Conference Call Participants

Brian Weinstein - William Blair

Daniel Brennan - Cowen & Company

David Westenberg - Piper Sandler

Derik De Bruin - Bank of America

Elizabeth Webster - Goldman Sachs

Mark Massaro - BTIG

Yuko Oku - Morgan Stanley

Julia Qin - JP Morgan

Operator

Good day, and thank you for standing by. Welcome to the Adaptive Biotechnologies Second Quarter 2022 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Karina Calzadilla, Head of Investor Relations. Please go ahead.

Karina Calzadilla

Thank you, Daniel. Thank you, Daniel, and good afternoon, everyone. I would like to welcome you to Adaptive Biotechnologies Second Quarter 2022 Earnings Conference Call. Earlier today, we issued a press release reporting Adaptive financial results for the second quarter of 2022. The press release is available at www.adaptivebiotech.com. We are conducting a live webcast of this call, and we'll be referencing to a slide presentation that has been posted to the Investors section in our corporate website.

During the call, management will make projections and other forward-looking statements within the meanings of federal security laws regarding future events and the future financial performance of the company. These statements reflect management's current perspective of the business as of today. Actual results may differ materially from today's forward-looking statements, depending on a number of factors, which are set forth in our public filings with the SEC and listed in this presentation.

Joining the call today are Chad Robins, our CEO and Co-Founder; and Tycho Peterson, our Chief Financial Officer. In addition, Harlan Robins, Adaptive’s Chief Scientific Officer and Co-Founder; Nitin Sood, Head of the immune -- MRD business; and Sharon Benzeno, Head of Immune Medicine business, will be available for Q&A.

With that, I'll turn the call to Chad Robins. Chad?

Chad Robins

Thanks, Karina. Good afternoon, everybody, and thank you for joining us on our second quarter 2022 earnings call. First, a big thank you to all our Adaptive employees for their continuous dedication and hard work in delivering another strong quarter. We're halfway through the year. We're on track to achieve our 2022 goals in both our MRD and Immune Medicine businesses.